The long-standing assumption that aggressive surgery improves mesothelioma outcomes faces new scrutiny as real-world data reveals chemotherapy-alone patients achieving comparable survival rates. This challenges decades of clinical practice where cytoreductive surgery was considered essential for extending life in this aggressive cancer.
Analysis of over 21,000 mesothelioma patients from the National Cancer Database found that those receiving chemotherapy but declining recommended surgery had nearly identical five-year survival rates (16.4%) as surgical patients when properly matched for disease characteristics. The median survival of 22.9 months in non-surgical patients closely paralleled surgical cohorts, with young age, academic center treatment, epithelioid histology, and early-stage disease driving better outcomes regardless of surgical intervention.
These findings reinforce the controversial MARS 2 trial results that questioned surgery's survival benefit, but now with vastly larger patient numbers spanning real-world clinical practice rather than controlled trial conditions. The data suggests that patient selection factors—tumor biology, age, and treatment center expertise—may matter more than the surgical procedure itself for long-term survival.
For mesothelioma patients facing treatment decisions, this represents a paradigm shift toward individualized care rather than reflexive surgical intervention. The analysis reveals that nearly 10% of all patients survived five years or longer, with surgical and non-surgical approaches achieving similar success rates when patient characteristics are equivalent. This evidence supports informed treatment discussions weighing quality of life considerations against aggressive interventions that may not extend survival.